Publications by authors named "H H Elkadi"

The global climate is under threat from increasing extreme heat, evidenced by rising temperatures and a surge in hot days. Heat waves are intensifying worldwide, impacting cities and residents, as demonstrated by the record-breaking heat experienced in the UK in 2022, which resulted in over 4500 deaths. Urban heat islands (UHIs) exacerbate these heat waves, making city residents more vulnerable to heat-related deaths.

View Article and Find Full Text PDF

In Transit-Oriented Development (TOD), the close integration of residential structures with community activities and traffic heightens residents' exposure to traffic-related pollutants. Despite traffic being a primary source of particulate matter (PM), the compact design of TODs, together with the impact of urban heat island (UHI), increases the likelihood of trapping emitted PM from traffic, leading to heightened exposure of TOD residents to PM. Although PM originates from two distinct sources in road traffic, exhaust and non-exhaust emissions (NEE), current legislation addressing traffic-related PM from non-exhaust emissions sources remains limited.

View Article and Find Full Text PDF

Introduction: There is wide variation in the management of simple subcutaneous abscesses in the UK and no national guidelines describing best practice. During the SARS-CoV-2 pandemic, regional or local anaesthesia (LA) use was recommended instead of general anaesthesia. This study aimed to assess the effect of anaesthetic use on outcomes following incision and drainage (I&D) of simple subcutaneous abscesses.

View Article and Find Full Text PDF

Background: An estimated 30% of women worldwide experience intimate partner violence (IPV) during their lifetime. Exposure to IPV is associated with poor health outcomes and the prevalence of violence may be higher amongst women seeking healthcare. Existing evidence from the Arab region is limited.

View Article and Find Full Text PDF

Objective: Evaluate efficacy of infliximab with response-driven dosing in patients with active RA.

Research Design And Methods: Patients (n = 203) with active RA despite methotrexate + etanercept/adalimumab, participated in this active-infliximab-switch study. Infliximab 3 mg/kg was infused at Weeks 0, 2, 6, 14, and 22 with escalation to 5 or 7 mg/kg depending on EULAR response at Weeks 14 and 22.

View Article and Find Full Text PDF